Nurix Therapeutics (NASDAQ:NRIX) Now Covered by Analysts at Leerink Partners

Leerink Partners initiated coverage on shares of Nurix Therapeutics (NASDAQ:NRIX) in a research report report published on Monday, Marketbeat Ratings reports. The brokerage issued a market perform rating and a $16.00 price objective on the stock.

Other equities analysts have also recently issued research reports about the stock. BTIG Research assumed coverage on shares of Nurix Therapeutics in a research note on Tuesday, December 10th. They issued a “buy” rating and a $35.00 price target for the company. BMO Capital Markets assumed coverage on shares of Nurix Therapeutics in a research note on Friday, December 6th. They issued an “outperform” rating and a $35.00 price target for the company. Stifel Nicolaus boosted their price target on shares of Nurix Therapeutics from $34.00 to $36.00 and gave the stock a “buy” rating in a research note on Wednesday, January 29th. Needham & Company LLC cut their price target on shares of Nurix Therapeutics from $29.00 to $28.00 and set a “buy” rating for the company in a research note on Wednesday, January 29th. Finally, HC Wainwright upped their price objective on shares of Nurix Therapeutics from $35.00 to $36.00 and gave the company a “buy” rating in a research note on Wednesday, January 29th. Three equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. According to data from MarketBeat, Nurix Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $30.88.

Nurix Therapeutics Trading Up 1.8 %

Nurix Therapeutics stock opened at $13.90 on Monday. The firm’s 50 day simple moving average is $17.22 and its 200 day simple moving average is $20.93. The firm has a market capitalization of $1.05 billion, a PE ratio of -4.81 and a beta of 2.18. Nurix Therapeutics has a 1-year low of $11.90 and a 1-year high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX) last released its quarterly earnings results on Tuesday, January 28th. The company reported ($0.75) EPS for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.08). Nurix Therapeutics had a negative return on equity of 53.65% and a negative net margin of 354.85%. Research analysts forecast that Nurix Therapeutics will post -2.99 earnings per share for the current year.

Insider Buying and Selling at Nurix Therapeutics

In other Nurix Therapeutics news, CFO Houte Hans Van sold 5,825 shares of the company’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $14.49, for a total value of $84,404.25. Following the completion of the transaction, the chief financial officer now directly owns 33,724 shares in the company, valued at approximately $488,660.76. This represents a 14.73 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Gwenn Hansen sold 3,690 shares of the company’s stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $19.85, for a total transaction of $73,246.50. Following the completion of the transaction, the insider now owns 55,937 shares of the company’s stock, valued at $1,110,349.45. This trade represents a 6.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 12,326 shares of company stock valued at $213,449 in the last quarter. Company insiders own 7.20% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. FMR LLC increased its stake in shares of Nurix Therapeutics by 1,711.9% in the 4th quarter. FMR LLC now owns 10,634,231 shares of the company’s stock worth $200,349,000 after acquiring an additional 10,047,329 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Nurix Therapeutics by 8.3% in the 4th quarter. Vanguard Group Inc. now owns 4,345,266 shares of the company’s stock worth $81,865,000 after acquiring an additional 333,452 shares in the last quarter. Wellington Management Group LLP increased its stake in shares of Nurix Therapeutics by 3.0% in the 4th quarter. Wellington Management Group LLP now owns 3,586,605 shares of the company’s stock worth $67,572,000 after acquiring an additional 104,500 shares in the last quarter. Soleus Capital Management L.P. increased its stake in shares of Nurix Therapeutics by 97.3% in the 4th quarter. Soleus Capital Management L.P. now owns 2,102,833 shares of the company’s stock worth $39,617,000 after acquiring an additional 1,036,999 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of Nurix Therapeutics by 9.5% in the 4th quarter. Geode Capital Management LLC now owns 1,585,127 shares of the company’s stock worth $29,870,000 after acquiring an additional 137,087 shares in the last quarter.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.